Canaccord Genuity Raises Price Target for BioMarin Pharmaceutical Inc.
Canaccord Genuity has increased its price target for BioMarin Pharmaceutical Inc. from $114 to $117.
Stocks · News reference
BioMarin Pharmaceutical Inc. is participating in an industrial collaboration focused on the scale-up and commercialization of sustainable oligonucleotide manufacturing technology.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity has increased its price target for BioMarin Pharmaceutical Inc. from $114 to $117.
Analyst Mitchell Kapoor of H.C. Wainwright has maintained a 'Hold' rating and a $60 price target for BioMarin Pharmaceutical Inc.
B. Riley has lowered its price target for BioMarin Pharmaceutical Inc. while maintaining a Buy rating on the stock.
Morgan Stanley analyst Sean Laaman has maintained a 'Buy' rating on BioMarin Pharmaceutical Inc. while adjusting the price target to $103 from $119.
BioMarin has submitted applications to the FDA and EMA to expand the therapeutic indication of its drug vosoritida to include the treatment of hypochondroplasia.